{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T18:18:34Z","timestamp":1792001914675,"version":"4.4.0"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2022,6,24]],"date-time":"2022-06-24T00:00:00Z","timestamp":1656028800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,11,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Thymic malignancies represent a heterogeneous group of rare thoracic cancers, which are classified according to the World Health Organization histopathologic classification, that distinguishes thymomas from thymic carcinomas. Data regarding the biology of those tumors are limited in the literature, and the vast majority have been obtained using surgical specimens from early-stage disease. Meanwhile, treatment of advanced, refractory thymic tumors currently relies on chemotherapy, with limited efficacy. Comprehensive genomic profiling (CGP) of advanced, refractory tumors would open some opportunities for innovative treatments.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Patients and Methods<\/jats:title>\n                  <jats:p>A total of 90 and 174 consecutive patients with thymoma or thymic carcinoma, respectively, for whom formalin-fixed, paraffin-embedded specimens from recurrent, refractory tumor were sequenced, were included. Sequencing was performed using hybridization-captured, adaptor ligation-based libraries to a mean coverage depth of &amp;gt;500\u00d7 for up to 315 cancer-related genes plus 37 introns from 28 genes frequently rearranged in cancer.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Thymomas featured a low frequency of genomic alterations (average of 1.8\/tumor), and low levels of TMB. The genomic alterations identified in more than 10% of cases were in the CDKN2A\/B and TP53 genes. Amplification in the NTRK1 gene was found in an unresectable, stage III, type B3 thymoma. Thymic carcinomas featured a significantly higher frequency of alterations at 4.0\/tumor (P &amp;lt; .0001). Clinically relevant genomic alterations were observed in the CDKN2A, KIT, and PTEN\/PI3K\/MTOR pathways. Elevated TMB in thymic carcinomas was uncommon with only 6% of cases featuring \u226510 mutations\/Mb.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Our cohort is the largest available so far, reporting on CGP of thymic epithelial tumors in the setting of advanced disease. The identification of clinically relevant genomic alterations in the KIT, PI3K, CDKN2A\/B, or NTRK genes provides a strong rationale for potential precision medicine approaches using targeted agents. A subset of thymic carcinomas show high tumor mutation burden, what may be a predictor of efficacy of immune checkpoint inhibitors.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyac115","type":"journal-article","created":{"date-parts":[[2022,6,24]],"date-time":"2022-06-24T17:11:12Z","timestamp":1656090672000},"page":"919-929","source":"Crossref","is-referenced-by-count":37,"title":["Comprehensive Genomic Profiling of 274 Thymic Epithelial Tumors Unveils Oncogenic Pathways and Predictive Biomarkers"],"prefix":"10.1093","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9909-2299","authenticated-orcid":false,"given":"Nicolas","family":"Girard","sequence":"first","affiliation":[{"name":"Institut Curie, Institut du Thorax Curie Montsouris , Paris , France"},{"name":"Facult\u00e9 de M\u00e9decine Simonbe Veil, UVSQ, Paris Saclay Campus , Versailles , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0523-0310","authenticated-orcid":false,"given":"Cl\u00e9mence","family":"Basse","sequence":"additional","affiliation":[{"name":"Institut Curie, Institut du Thorax Curie Montsouris , Paris , France"},{"name":"Facult\u00e9 de M\u00e9decine Simonbe Veil, UVSQ, Paris Saclay Campus , Versailles , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexa","family":"Schrock","sequence":"additional","affiliation":[{"name":"Foundation Medicine , Cambridge, MA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shakti","family":"Ramkissoon","sequence":"additional","affiliation":[{"name":"Foundation Medicine , Cambridge, MA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Killian","sequence":"additional","affiliation":[{"name":"Foundation Medicine , Cambridge, MA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey S","family":"Ross","sequence":"additional","affiliation":[{"name":"Foundation Medicine , Cambridge, MA , USA"},{"name":"SUNY Upstate Medical University , Syracuse, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,6,24]]},"reference":[{"issue":"10","key":"2022110514275073400_CIT0001","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1097\/JTO.0000000000000654","article-title":"The 2015 World Health Organization classification of tumors of the thymus: continuity and changes.","volume":"10","author":"Marx","year":"2015","journal-title":"J Thorac Oncol"},{"issue":"3","key":"2022110514275073400_CIT0002","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1093\/ejcts\/ezt649","article-title":"Tumours of the thymus: a cohort study of prognostic factors from the European Society of Thoracic Surgeons database.","volume":"46","author":"Ruffini","year":"2014","journal-title":"Eur J Cardiothorac Surg"},{"issue":"4","key":"2022110514275073400_CIT0003","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1097\/JTO.0000000000000128","article-title":"Thymic carcinoma: a cohort study of patients from the European society of thoracic surgeons database.","volume":"9","author":"Ruffini","year":"2014","journal-title":"J Thorac Oncol"},{"key":"2022110514275073400_CIT0004","doi-asserted-by":"crossref","first-page":"v40","DOI":"10.1093\/annonc\/mdv277","article-title":"Thymic epithelial tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.","volume":"26","author":"Girard","year":"2015","journal-title":"Ann Oncol"},{"issue":"76","key":"2022110514275073400_CIT0005","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/S0003-4975(03)00555-1","article-title":"Therapy for thymic epithelial tumors: a clinical study of 1,320 patients from Japan.","volume":"76","author":"Kondo","year":"2003","journal-title":"Ann Thorac Surg"},{"key":"2022110514275073400_CIT0006","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1097\/JTO.0000000000000290","article-title":"The IASLC\/ITMIG Thymic Epithelial Tumors Staging Project: proposal for an evidence-based stage classification system for the forthcoming (8th) edition of the TNM classification of malignant tumors.","volume":"9","author":"Detterbeck","year":"2014","journal-title":"J Thorac Oncol"},{"issue":"11","key":"2022110514275073400_CIT0007","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1016\/j.jtho.2018.08.005","article-title":"Chemotherapy in advanced thymic epithelial tumors: insights from the RYTHMIC prospective cohort.","volume":"13","author":"Merveilleux Du Vignaux","year":"2018","journal-title":"J Thorac Oncol."},{"issue":"22","key":"2022110514275073400_CIT0008","doi-asserted-by":"crossref","first-page":"6790","DOI":"10.1158\/1078-0432.CCR-09-0644","article-title":"Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas.","volume":"15","author":"Girard","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"9","key":"2022110514275073400_CIT0009","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1200\/JCO.2014.58.2007","article-title":"Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial.","volume":"33","author":"Lopez-Chavez","year":"2015","journal-title":"J Clin Oncol"},{"key":"2022110514275073400_CIT0010","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/nbt.2696","article-title":"Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing.","volume":"31","author":"Frampton","year":"2013","journal-title":"Nat Biotechnol"},{"issue":"3","key":"2022110514275073400_CIT0011","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1470-2045(18)30062-7","article-title":"Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study.","volume":"19","author":"Giaccone","year":"2018","journal-title":"Lancet Oncol"},{"issue":"11","key":"2022110514275073400_CIT0012","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1002\/1097-0142(19811201)48:11<2485::AID-CNCR2820481123>3.0.CO;2-R","article-title":"Follow-up study of thymomas with special reference to their clinical stages.","volume":"48","author":"Masaoka","year":"1981","journal-title":"Cancer"},{"key":"2022110514275073400_CIT0013","doi-asserted-by":"crossref","first-page":"D805","DOI":"10.1093\/nar\/gku1075","article-title":"COSMIC: exploring the world\u2019s knowledge of somatic mutations in human cancer.","volume":"43","author":"Forbes","year":"2015","journal-title":"Nucleic Acids Res"},{"key":"2022110514275073400_CIT0014","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13073-017-0424-2","article-title":"Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden.","volume":"9","author":"Chalmers","year":"2017","journal-title":"Genome Med"},{"issue":"2","key":"2022110514275073400_CIT0015","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/JTO.0000000000000393","article-title":"The impact of thymoma histotype on prognosis in a worldwide database.","volume":"10","author":"Weis","year":"2015","journal-title":"J Thorac Oncol"},{"key":"2022110514275073400_CIT0016","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.humpath.2017.08.018","article-title":"Thymoma: a clinicopathological correlation of 1470 cases","volume":"73","author":"Weissferdt","year":"2018","journal-title":"Hum Pathol"},{"issue":"10","key":"2022110514275073400_CIT0017","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/j.jtho.2017.06.072","article-title":"Assessment of the ITMIG statement on the WHO histological classification and of the eighth TNM staging of thymic epithelial tumors of a series of 188 thymic epithelial tumors.","volume":"12","author":"Meurgey","year":"2017","journal-title":"J Thorac Oncol"},{"key":"2022110514275073400_CIT0018","doi-asserted-by":"crossref","first-page":"e351","DOI":"10.1038\/cddis.2012.92","article-title":"Copy number aberrations of BCL2 and CDKN2A\/B identified by array-CGH in thymic epithelial tumors.","volume":"3","author":"Petrini","year":"2012","journal-title":"Cell Death Dis"},{"key":"2022110514275073400_CIT0019","doi-asserted-by":"crossref","first-page":"7336","DOI":"10.1038\/srep07336","article-title":"Mutations of epigenetic regulatory genes are common in thymic carcinomas.","volume":"4","author":"Wang","year":"2014","journal-title":"Sci Rep"},{"issue":"2","key":"2022110514275073400_CIT0020","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.ccell.2018.01.003","article-title":"The integrated genomic landscape of thymic epithelial tumors.","volume":"33","author":"Radovich","year":"2018","journal-title":"Cancer Cell"},{"key":"2022110514275073400_CIT0021","doi-asserted-by":"crossref","first-page":"S131","DOI":"10.1097\/JTO.0000000000000298","article-title":"State of the art of genetic alterations in thymic epithelial tumors.","volume":"9","author":"Rajan","year":"2014","journal-title":"J Thorac Oncol"},{"issue":"2","key":"2022110514275073400_CIT0022","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S1470-2045(14)71181-7","article-title":"Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial.","volume":"16","author":"Thomas","year":"2015","journal-title":"Lancet Oncol"},{"key":"2022110514275073400_CIT0023","doi-asserted-by":"crossref","first-page":"S346","DOI":"10.1016\/j.jtho.2018.08.297","article-title":"OA11.05 phase II study of sunitinib in patients with thymic carcinoma previously treated with platinum-based chemotherapy (KOSMIC Trial).","volume":"13","author":"Kim","year":"2018","journal-title":"J Thorac Oncol"},{"issue":"8","key":"2022110514275073400_CIT0024","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/j.jtho.2016.04.013","article-title":"PI3K as a potential therapeutic target in thymic epithelial tumors.","volume":"11","author":"Alberobello","year":"2016","journal-title":"J Thorac Oncol"},{"issue":"114","key":"2022110514275073400_CIT0025","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/bjc.2015.425","article-title":"A large microRNA cluster on chromosome 19 is a transcriptional hallmark of WHO type A and AB thymomas.","volume":"114","author":"Radovich","year":"2016","journal-title":"Br J Cancer"},{"issue":"6","key":"2022110514275073400_CIT0026","doi-asserted-by":"crossref","first-page":"890","DOI":"10.18632\/oncotarget.1015","article-title":"Thymoma patients treated in a phase I clinic at MD Anderson Cancer Center: responses to mTOR inhibitors and molecular analyses.","volume":"4","author":"Wheler","year":"2013","journal-title":"Oncotarget"},{"issue":"4","key":"2022110514275073400_CIT0027","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1200\/JCO.2017.74.4078","article-title":"Phase II study of Everolimus in patients with Thymoma and Thymic carcinoma previously treated with Cisplatin-based chemotherapy.","volume":"36","author":"Zucali","year":"2018","journal-title":"J Clin Oncol"},{"issue":"6","key":"2022110514275073400_CIT0028","doi-asserted-by":"crossref","first-page":"e881","DOI":"10.1634\/theoncologist.2019-0641","article-title":"Antitumor activity of larotrectinib in esophageal carcinoma with NTRK gene amplification.","volume":"25","author":"Hempel","year":"2020","journal-title":"Oncologist"},{"issue":"19","key":"2022110514275073400_CIT0029","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1001\/jama.2014.3741","article-title":"Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs.","volume":"311","author":"Kris","year":"2014","journal-title":"JAMA"},{"issue":"5","key":"2022110514275073400_CIT0030","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1084\/jem.191.5.891","article-title":"Facilitation of beta selection and modification of positive selection in the thymus of PD-1-deficient mice.","volume":"191","author":"Nishimura","year":"2000","journal-title":"J Exp Med"},{"issue":"22","key":"2022110514275073400_CIT0031","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1801946","article-title":"Nivolumab plus Ipilimumab in lung cancer with a high tumor mutational burden.","volume":"378","author":"Hellmann","year":"2018","journal-title":"N Engl J Med"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/27\/11\/919\/46832530\/oyac115.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/27\/11\/919\/46832530\/oyac115.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,5]],"date-time":"2022-11-05T14:28:53Z","timestamp":1667658533000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/27\/11\/919\/6617572"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,24]]},"references-count":31,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,6,24]]},"published-print":{"date-parts":[[2022,11,3]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyac115","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,11,1]]},"published":{"date-parts":[[2022,6,24]]}}}